USP7 and B-cell chronic lymphocytic leukemia: Given the involvement of USP7 in multiple cellular pathways, its expression is often dysregulated in human malignancies, making it an oncogene that promotes tumor growth and negatively affects the immune response to tumors [22], such as in chronic lymphocytic leukemia, acute lymphocytic leukemia (ALL), and multiple myeloma [23,24].